UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lessons from a failed γ-secretase Alzheimer trial

Cell, 2014-11, Vol.159 (4), p.721-726

De Strooper, Bart

2014

Volltextzugriff (PDF)

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

Journal of clinical oncology, 2014-01, Vol.32 (1), p.44-50

2014

Volltextzugriff (PDF)

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

Journal of clinical oncology, 2016-04, Vol.34 (12), p.1368-1375

2016

Volltextzugriff (PDF)

Design, Synthesis, and Evaluation of Thienodiazepine Derivatives as Positron Emission Tomography Imaging Probes for Bromodomain and Extra-Terminal Domain Family Proteins

Journal of medicinal chemistry, 2021-10, Vol.64 (19), p.14745-14756

2021

Volltextzugriff (PDF)

Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery

Scientific reports, 2020-11, Vol.10 (1), p.19285, Article 19285

2020

Volltextzugriff (PDF)

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Clinical cancer research, 2018-12, Vol.24 (24), p.6142-6149

2018

Volltextzugriff (PDF)

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Clinical cancer research, 2012-11, Vol.18 (21), p.6058-6064

2012

Volltextzugriff (PDF)

Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma

Nanomedicine (London, England), 2014-05, Vol.9 (6), p.839-849

2014

Volltextzugriff (PDF)

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Clinical cancer research, 2012-09, Vol.18 (17), p.4775-4784

2012

Volltextzugriff (PDF)

In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232

The Journal of pharmacology and experimental therapeutics, 2013-11, Vol.347 (2), p.478-486

2013

Volltextzugriff (PDF)

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men

Sleep (New York, N.Y.), 2013-02, Vol.36 (2), p.259-267

2013

Volltextzugriff (PDF)

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

Clinical cancer research, 2012-09, Vol.18 (17), p.4764-4774

2012

Volltextzugriff (PDF)

Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

International journal of clinical practice (Esher), 2014-12, Vol.68 (12), p.1429-1441

Citrome, L.

2014

Volltextzugriff (PDF)

New Positron Emission Tomography (PET) Radioligand for Imaging σ‑1 Receptors in Living Subjects

Journal of medicinal chemistry, 2012-10, Vol.55 (19), p.8272-8282

2012

Volltextzugriff (PDF)

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Clinical cancer research, 2018-12, Vol.24 (24), p.6150-6159

2018

Volltextzugriff (PDF)

Daidzein-loaded nanostructured lipid carriers-PLGA nanofibers for transdermal delivery

International journal of pharmaceutics, 2016-03, Vol.501 (1-2), p.245-252

2016

Volltextzugriff (PDF)

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

Journal of clinical pharmacology, 2022-02, Vol.62 (2), p.206-219

2022

Volltextzugriff (PDF)

A novel, sensitive, and widely accessible besifloxacin quantification method by HPLC-fluorescence: Application to an ocular pharmacokinetic study

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021-11, Vol.1185, p.123010, Article 123010

2021

Volltextzugriff (PDF)

Production of the Bengamide Class of Marine Natural Products in Myxobacteria: Biosynthesis and Structure-Activity Relationships

Angewandte Chemie (International ed.), 2015-12, Vol.54 (51), p.15560-15564

International ed. in English, 2015

Volltextzugriff (PDF)

Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter

Toxicology and applied pharmacology, 2022-01, Vol.434, p.115823, Article 115823

2022

Volltextzugriff (PDF)

Development of In Vitro–In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls

Journal of pharmaceutical sciences, 2015-09, Vol.104 (9), p.2913-2922

2015

Volltextzugriff (PDF)

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

Haematologica (Roma), 2017-04, Vol.102 (4), p.719-727

2017

Volltextzugriff (PDF)

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

Journal of medicinal chemistry, 2009-02, Vol.52 (4), p.904-907

2009

Volltextzugriff (PDF)

1 – 25 von 441

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(391)
Mit Volltextzugriff
(322)

Publikationsform

Artikel
(441)

Sprache

Englisch
(416)
Japanisch
(71)
Chinesisch
(23)
Deutsch
(2)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(347)
Life Sciences & Biomedicine
(340)
Animals
(282)
Pharmacology & Pharmacy
(270)
Humans
(252)
Azepines - Pharmacokinetics
(238)
Male
(237)
Azepines - Pharmacology
(198)
Biological And Medical Sciences
(198)
Medical Sciences
(191)
Pharmacology. Drug Treatments
(175)
Female
(133)
Rats
(129)
Azepines - Administration & Dosage
(103)
Adult
(93)
Chemistry
(83)
Mice
(82)
Azepines - Chemistry
(80)
Physical Sciences
(80)
Chemistry, Medicinal
(75)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lessons from a failed γ-secretase Alzheimer trial

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial

Design, Synthesis, and Evaluation of Thienodiazepine Derivatives as Positron Emission Tomography Imaging Probes for Bromodomain and Extra-Terminal Domain Family Proteins

Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment of Insomnia

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Targeted delivery of silver nanoparticles and alisertib: in vitro and in vivo synergistic effect against glioblastoma

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

New Positron Emission Tomography (PET) Radioligand for Imaging σ‑1 Receptors in Living Subjects

Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma

Daidzein-loaded nanostructured lipid carriers-PLGA nanofibers for transdermal delivery

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies

A novel, sensitive, and widely accessible besifloxacin quantification method by HPLC-fluorescence: Application to an ocular pharmacokinetic study

Production of the Bengamide Class of Marine Natural Products in Myxobacteria: Biosynthesis and Structure-Activity Relationships

Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter

Development of In Vitro–In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

Suchergebnisse filtern